Literature DB >> 9055830

Antidepressant and double antidepressant treatment for the affective disorder of epilepsy.

D Blumer1.   

Abstract

BACKGROUND: About half of all patients with chronic epilepsy experience an intermittent and polysymptomatic affective disorder; fewer than 10% suffer from interictal psychotic episodes. The affective disorder responds well to treatment with tricyclic antidepressant medication. The interictal psychosis tends to develop among those with severe affective disorder, responds poorly to antipsychotic medication, and has been more difficult to treat.
METHOD: At the Epi-Care Center, Memphis, Tennessee, we have recently begun to treat refractory cases, both nonresponders with affective disorder and those with interictal psychosis, with the combination of a tricyclic antidepressant (TCA) and a serotonin selective reuptake inhibitor (SSRI). The double antidepressant treatment of all previously intractable patients with interictal affective disorder seen over a 20-month period at the Epi-Care Center is reported here.
RESULTS: The outcome of the novel treatment for the most severe psychiatric disorders of epilepsy has been highly satisfactory: 15 (68%) of 22 previously unresponsive patients with affective disorder were excellent or good responders.
CONCLUSION: Antidepressants are the psychotropic drugs of choice for the affective disorder of epilepsy and can be effective in combined form (TCA and SSRI) for otherwise intractable patients. The paradoxical therapeutic effects of proconvulsant drugs in epilepsy conform with the hypothesis that the psychiatric complications of chronic epilepsy result from the development of seizure-suppressing mechanisms that can be mitigated by antidepressants.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9055830     DOI: 10.4088/jcp.v58n0101

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

Review 1.  The relationship of psychiatric illnesses and seizures.

Authors:  N D Tsopelas; R Saintfort; G L Fricchione
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

2.  Depression in Individuals with Epilepsy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-11       Impact factor: 3.598

3.  Interleukin-1β causes fluoxetine resistance in an animal model of epilepsy-associated depression.

Authors:  Eduardo A Pineda; Julie G Hensler; Raman Sankar; Don Shin; Teresa F Burke; Andréy M Mazarati
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 4.  Neuropsychiatric complications of epilepsy.

Authors:  Andres M Kanner; Susan Palac
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 5.  Epilepsy Associated Depression: An Update on Current Scenario, Suggested Mechanisms, and Opportunities.

Authors:  Tanveer Singh; Rajesh Kumar Goel
Journal:  Neurochem Res       Date:  2021-03-04       Impact factor: 3.996

Review 6.  Antidepressants for people with epilepsy and depression.

Authors:  Melissa J Maguire; Jennifer Weston; Jasvinder Singh; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2014-12-03

7.  Managing depressive disorders in patients with epilepsy.

Authors:  Madhukar H Trivedi; Ben T Kurian
Journal:  Psychiatry (Edgmont)       Date:  2007-01

Review 8.  Complex partial seizures and depression.

Authors:  Brian A Greenlee; Richard B Ferrell; Christopher I Kauffman; Thomas W McAllister
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

Review 9.  Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review.

Authors:  Martin J Brodie; Frank Besag; Alan B Ettinger; Marco Mula; Gabriella Gobbi; Stefano Comai; Albert P Aldenkamp; Bernhard J Steinhoff
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

10.  Antidepressants for people with epilepsy and depression.

Authors:  Melissa J Maguire; Anthony G Marson; Sarah J Nevitt
Journal:  Cochrane Database Syst Rev       Date:  2021-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.